77,242 Shares in VanEck Biotech ETF $BBH Purchased by Quantitative Investment Management LLC

Quantitative Investment Management LLC bought a new position in VanEck Biotech ETF (NASDAQ:BBH) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 77,242 shares of the company’s stock, valued at approximately $7,589,000. VanEck Biotech ETF makes up approximately 0.8% of Quantitative Investment Management LLC’s investment portfolio, making the stock its 26th largest position. Quantitative Investment Management LLC owned 3.96% of VanEck Biotech ETF at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Segall Bryant & Hamill LLC purchased a new position in shares of VanEck Biotech ETF in the first quarter valued at $881,000. Paragon Private Wealth Management LLC lifted its holdings in VanEck Biotech ETF by 5.3% during the 1st quarter. Paragon Private Wealth Management LLC now owns 15,368 shares of the company’s stock worth $2,890,000 after purchasing an additional 775 shares in the last quarter. Bank of America Corp DE boosted its stake in VanEck Biotech ETF by 44.3% in the 1st quarter. Bank of America Corp DE now owns 66,338 shares of the company’s stock worth $12,473,000 after purchasing an additional 20,375 shares during the period. Royal Bank of Canada boosted its stake in VanEck Biotech ETF by 4.3% in the 1st quarter. Royal Bank of Canada now owns 13,843 shares of the company’s stock worth $2,603,000 after purchasing an additional 565 shares during the period. Finally, Wealthfront Advisers LLC grew its holdings in VanEck Biotech ETF by 27.0% during the 1st quarter. Wealthfront Advisers LLC now owns 7,004 shares of the company’s stock valued at $1,317,000 after buying an additional 1,491 shares in the last quarter. Institutional investors own 32.05% of the company’s stock.

Insider Buying and Selling

In other VanEck Biotech ETF news, major shareholder Sardar Biglari sold 6,533 shares of the firm’s stock in a transaction dated Wednesday, July 15th. The stock was sold at an average price of $16.71, for a total transaction of $109,166.43. Following the sale, the insider owned 3,552,710 shares in the company, valued at $59,365,784.10. This trade represents a 0.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Over the last three months, insiders have sold 10,493 shares of company stock valued at $175,335.

VanEck Biotech ETF Price Performance

VanEck Biotech ETF stock opened at $236.48 on Monday. The firm’s 50 day simple moving average is $212.95 and its 200 day simple moving average is $197.11. VanEck Biotech ETF has a 1-year low of $160.91 and a 1-year high of $244.35.

VanEck Biotech ETF Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.